The sellside hacks back Lynparza’s prostate opportunity
The writing had been on the wall for Parp inhibitors in first-line prostate cancer, and last week’s US panel showed no mercy.
Point looks to turn the tables on Novartis
Conventional wisdom says manufacturing takes second place to clinical development, but Point turned that on its head, and now a big catalyst approaches.
Asco-GU – Talzenna remains a wait-and-see story in prostate cancer
Talapro-2 data backing Talzenna in all-comers are slated by Asco-GU’s discussant, as Lynparza shows precisely what might go wrong.
Pfizer reignites the Parp biomarker debate
Talzenna scores in first-line prostate cancer irrespective of HRR status, but for now we only have Pfizer’s word for it.
FDA scrutiny now hits Parp inhibitors
A November adcom could decide whether Zejula will lose yet more ground to Lynparza.